Teva pharmaceuticals has secured a funding round with Blackstone Life Sciences(BXLS) to accelerate development of its promising drug, duvakitug. Distributed over a 4 year period, the capital is specifically earmarked to support the clinical progress of the therapy and as it moves through critical late stage testing.

Duvakitug is a human monoclonal antibody designed to target TL1A, a protein associated with inflammation. It is currently in phase 3 clinical trials for the treatment of Ulcerative Colitis (UC) and Crohn’s Disease (CD). The financing from Blackstone follows a successful phase2b trial, where the drug provided durable, meaningful relief for patients suffering from this chronic condition.

While Teva continues to co-develop and co-commercialize the drug with Sanofi under a previous 2023 agreement, the financing from Blackstone adds a robust layer of external financing.

In exchange for the financing, Blackstone is eligible to receive regulatory and commercial milestone payments, as well as royalties on global sales once the drug reaches the market. The collaboration between Teva, Sanofi and Blackstone highlights the shared confidence that duvakitug could become a best in class therapy in the rapidly expanding immunology sector.